Darin Lippoldt Biography and Net Worth

Darin M. Lippoldt J.D. serves as Chief Legal Officer and Corporate Secretary of the Company. He was appointed Chief Legal Officer and Corporate Secretary in October 2014 and has oversight of all corporate legal matters, intellectual property, and corporate compliance. Prior to joining Neurocrine Biosciences, Mr. Lippoldt served as Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of Volcano Corporation, a company he joined in 2010. Prior to Volcano, Mr. Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law firms of Fulbright & Jaworski LLP and Matthews and Branscomb, P.C. Mr. Lippoldt received a B.B.A. in Finance, an M.A. in International Relations and a J.D. from St. Mary’s University.

What is Darin Lippoldt's net worth?: The estimated net worth of Darin Lippoldt is at least $3.97 million as of January 22nd, 2024. Mr. Lippoldt owns 35,882 shares of Neurocrine Biosciences stock worth more than $3,973,932 as of March 14th. This net worth approximation does not reflect any other assets that Mr. Lippoldt may own. Additionally, Mr. Lippoldt receives an annual salary of $921,010.00 as Insider at Neurocrine Biosciences. Learn More about Darin Lippoldt's net worth.
How old is Darin Lippoldt?: Mr. Lippoldt is currently 58 years old. There are 7 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 66 years old. Learn More on Darin Lippoldt's age.
What is Darin Lippoldt's salary?: As the Insider of Neurocrine Biosciences, Inc., Mr. Lippoldt earns $921,010.00 per year. There are 5 executives that earn more than Mr. Lippoldt. The highest earning executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who commands a salary of $2,050,000.00 per year. Learn More on Darin Lippoldt's salary.
How do I contact Darin Lippoldt?: The corporate mailing address for Mr. Lippoldt and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at ir@neurocrine.com. Learn More on Darin Lippoldt's contact information.
Has Darin Lippoldt been buying or selling shares of Neurocrine Biosciences?: Darin Lippoldt has not been actively trading shares of Neurocrine Biosciences during the past quarter. Most recently, Darin Lippoldt sold 10,000 shares of the business's stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $139.86, for a transaction totalling $1,398,600.00. Following the completion of the sale, the insider now directly owns 35,882 shares of the company's stock, valued at $5,018,456.52. Learn More on Darin Lippoldt's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 34 times. They sold a total of 517,095 shares worth more than $73,755,571.93. The most recent insider tranaction occured on February, 13th when CFO Matt Abernethy sold 2,558 shares worth more than $298,927.88. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 2/13/2025.

Darin Lippoldt Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/22/2024	Sell	10,000	$139.86	$1,398,600.00	35,882
12/6/2023	Sell	20,830	$119.86	$2,496,683.80	35,882
11/27/2023	Sell	10,919	$112.27	$1,225,876.13	35,882
11/3/2022	Sell	4,518	$125.02	$564,840.36	29,234
11/1/2022	Sell	10,000	$120.09	$1,200,900.00	29,234
10/27/2022	Sell	4,923	$115.04	$566,341.92	29,234
3/22/2022	Sell	8,455	$95.05	$803,647.75
3/18/2022	Sell	300	$95.00	$28,500.00
7/9/2020	Sell	1,657	$136.02	$225,385.14	27,678
5/18/2020	Sell	5,000	$120.00	$600,000.00	31,021
11/8/2019	Sell	10,000	$110.01	$1,100,100.00	26,728
9/3/2019	Sell	6,736	$100.00	$673,600.00
8/27/2019	Sell	3,264	$100.05	$326,563.20	21,625
8/23/2019	Sell	1,664	$100.09	$166,549.76	21,625
7/30/2019	Sell	15,831	$92.13	$1,458,510.03	160,732
1/3/2018	Sell	1,979	$79.36	$157,053.44
12/28/2017	Sell	15,237	$75.00	$1,142,775.00
12/28/2017	Sell	15,237	$75.00	$1,142,775.00	28,394
12/8/2017	Sell	2,955	$75.00	$221,625.00	16,112
12/4/2017	Sell	6,279	$75.04	$471,176.16	19,436
11/15/2017	Sell	9,900	$73.05	$723,195.00
11/9/2015	Sell	23,761	$52.92	$1,257,432.12

See Full Table

Darin Lippoldt Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $110.75

$108.03

$111.27

50 Day Range

MA: $129.69

$107.22

$153.29

2 Week Range

Now: $110.75

$105.18

$157.98

Volume

1,070,142 shs

Average Volume

1,343,585 shs

Market Capitalization

$11.04 billion

P/E Ratio

33.66

Dividend Yield

N/A

Beta

0.35

Darin Lippoldt Biography and Net Worth

What is Darin Lippoldt's net worth?

How old is Darin Lippoldt?

What is Darin Lippoldt's salary?

How do I contact Darin Lippoldt?

Has Darin Lippoldt been buying or selling shares of Neurocrine Biosciences?

Who are Neurocrine Biosciences' active insiders?

Are insiders buying or selling shares of Neurocrine Biosciences?